Aptevo Therapeutics(APVO)
SEATTLE, WA
BiotechnologyFocus: Oncology and hematology therapeutics, Bispecific Antibody
Aptevo Therapeutics is a life sciences company focused on Oncology and hematology therapeutics, Bispecific Antibody.
HematologyOncology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
20 mg/kg TRU-016 + Rituximab
Chronic Lymphocytic LeukemiaClinical Trials (1)
NCT01644253Phase 1b Safety and Efficacy Study of TRU-016
Phase 1APVO436
Acute Myeloid Leukemia (AML)Clinical Trials (1)
NCT06634394APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Phase 1Phase 1
Clinical Trials (1)
NCT00614042Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma
Phase 1APVO436
AMLClinical Trials (1)
NCT04973618Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
Phase 1APVO436
AMLClinical Trials (1)
NCT03647800Study of APVO436 in Patients With AML or MDS
Phase 1APVO210
PsoriasisClinical Trials (1)
NCT03768219Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis
Phase 1ES414
Prostate CancerClinical Trials (1)
NCT02262910Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
Phase 1Phase 1
Clinical Trials (1)
NCT01317901A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Phase 1TRU-016 and bendamustine
Chronic Lymphocytic Leukemia (CLL)Clinical Trials (1)
NCT01188681Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
Phase 1/2ALG.APV-527
Solid TumorOpen Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 9 clinical trials
SEC Filings: 2 available